Insights from Digital Pharma Leaders
Refine search
Pharmaceutical
The European Medicines Agency and national regulators across the European Union have published a workplan outlining how artificial intelligence and large health datasets will be used to support medicines regulation over the coming years. 13 March 2026
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. 13 March 2026
Pharmaceutical
For years, AI in pharma largely remained in the innovation phase. Companies ran pilot programs, formed partnerships and showcased demonstrations, but there was limited impact on how organizations were structured, how teams worked or how decisions were made. 11 March 2026
Pharmaceutical
Danish neuroscience specialist Lundbeck has appointed Markus Kede as senior vice president and chief AI officer, creating a new executive role to accelerate the company’s use of artificial intelligence across research and commercial operations. 10 March 2026
Pharmaceutical
US drugmaker Eli Lilly has launched a new NVIDIA-powered supercomputer, dubbed LillyPod, as part of a broader effort to embed artificial intelligence across its research and manufacturing operations. 27 February 2026
Pharmaceutical
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry. 25 February 2026
Pharmaceutical
US pharma giant Merck & Co and hospital system Mayo Clinic have announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data, to support drug discovery and development. 19 February 2026
Biotechnology
Following on from a host of successful or planned initial public offerings (IPOs) in biotech so far this year, another firm has lined up a listing. 6 February 2026
Pharmaceutical
The US Department of Health and Human Services (HHS) has sharply expanded its use of artificial intelligence, listing around 450 AI use cases across the department in a newly published fiscal 2025 inventory. 4 February 2026
Pharmaceutical
US AI-driven biotech Insilico Medicine has struck a strategic drug discovery partnership with Chinese pharma group Qilu Pharmaceutical, aiming to develop small-molecule therapies for cardiometabolic diseases using artificial intelligence. 2 February 2026
Pharmaceutical
Tech giant Nvidia and pharma major Eli Lilly have announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. 1 February 2026
Pharmaceutical
Swiss biotech startup FluoSphera has raised 1.23 million euros ($1.34 million) to expand commercial activity and advance its AI-driven imaging platform for preclinical drug testing. The funding round was led by Soulmates Ventures, with participation from a Swiss business angel and IndieBio New York. 12 January 2026
Biotechnology
Noetik, an AI-native biotech company developing self-supervised machine learning and high-throughput spatial data to develop cancer therapeutics, has announced a five-year strategic collaboration and AI model licensing agreement with UK pharma major GSK. 9 January 2026
Biotechnology
Danish biotech Genmab has partnered with artificial intelligence company Anthropic to deploy agentic AI tools across parts of its clinical development operations. The collaboration centers on custom Claude-powered systems designed to support data processing, analysis, and document generation as programs move toward regulatory milestones. 8 January 2026
Pharmaceutical
US biotech BostonGene has struck a research collaboration with British pharma AstraZeneca to explore the use of multimodal artificial intelligence in oncology drug development. 7 January 2026
Pharmaceutical
Artificial intelligence remains the most impactful technology shaping the pharmaceutical industry, with companies increasingly embedding it across research, development, and commercialization, according to GlobalData. The firm says AI is becoming central as drugmakers seek efficiency gains, lower costs, and improved patient outcomes. 24 December 2025
Pharmaceutical
An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life Sciences and partner. 18 December 2025
Pharmaceutical
South Korea-based Lunit, a provider of AI for cancer diagnostics and precision oncology, has announced a deal with Japanese drugmaker Daiichi Sankyo. 16 December 2025
Pharmaceutical
Medra, a US company developing the first platform for physical AI scientists, has announced a $52 million Series A financing. 12 December 2025
Pharmaceutical
Digital health stakeholders - including developers, policymakers, payers, and providers - are actively shaping and accelerating the adoption of digital health solutions, according to a new report from IQVIA. 12 December 2025
Pharmaceutical
Artificial intelligence is already well established in drug discovery, but the next big test for pharmaceuticals may be less glamorous: making more medicines, more reliably, from existing factories. 15 June 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a regulatory sandbox to examine how artificial intelligence (AI) could support medicines development and drug safety assessment. 9 June 2026
Biotechnology
French pharma major Sanofi has expanded its collaboration with French-American AI biotech Owkin through a multi-year agreement to develop artificial intelligence agents for drug research and development. 8 June 2026
Biotechnology
US pharma giant Pfizer has signed a license agreement with San Francisco-based Chai Discovery, giving its scientists access to the AI company’s drug discovery platform for biologics research. 5 June 2026
Pharmaceutical
US biopharma Alnylam Pharmaceuticals has signed a strategic AI collaboration with Inceptive Nucleics, as it looks to speed up the discovery of RNA interference therapies and broaden its pipeline under its Alnylam 2030 strategy. 4 June 2026
Biotechnology
Danish CNS specialist Lundbeck (and Cradle, a Dutch AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. 3 June 2026
Pharmaceutical
German techbio company Lucera has launched with ambitions to improve decision-making across pharmaceutical research and development using artificial intelligence and a curated biomedical knowledge base. 2 June 2026
Biotechnology
British techbio Genomics has launched Mystra AI, a human genetics-based artificial intelligence platform designed to help drugmakers identify and validate better targets for drug discovery. 2 June 2026
Biotechnology
Genesis Molecular AI and Incyte announced a new kind of deal, with Incyte’s proprietary experimental data powering large-scale training of Genesis’ drug discovery platform. It is backed with $120 million upfront and approximately $5 billion for up to 20 potential targets. 21 May 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has signed a broad artificial intelligence partnership with Anthropic, deploying the tech company’s Claude platform across research, clinical development, manufacturing, commercial operations and corporate functions. 21 May 2026
Pharmaceutical
Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work. 20 May 2026
Pharmaceutical
Chicago, USA-based artificial intelligence company Tempus AI announced a new initiative with US pharma major Bristol Myers Squibb. 15 May 2026
Pharmaceutical
US AI leader Anthropic is expanding further into healthcare and drug development through a new four-year partnership with the Gates Foundation focused on vaccines, disease modeling and health-system operations in lower-income countries. 15 May 2026
Biotechnology
UK-based Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, has raised $2.1 billion in a Series B financing round. 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Pharmaceutical
British pharma major AstraZeneca is expanding its oncology-focused artificial intelligence collaboration with US biotech Immunai in a deal that could bring the smaller company up to $37.5 million over 2026-2027. 8 May 2026
Pharmaceutical
Ahead of a London event on May 12 on how AI is rapidly reshaping how healthcare information is discovered, interpreted and shared, this week's Expert View comes from panellist Sophie Randall, Director of the Patient Information Forum, the UK membership organization for people working in health information and support. 6 May 2026
Biotechnology
Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. 28 April 2026
Biotechnology
Belgian drugmaker UCB and the University of Southampton have announced a joint three-year project that they have dubbed the Digital Antibody Research Collaboration (DARC). 27 April 2026
Pharmaceutical
Merck & Co and Google Cloud have announced a landmark partnership to enhance the US pharma giant’s digital backbone as an AI-enabled enterprise. 23 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze